

Alexander Grabner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5049974/publications.pdf>

Version: 2024-02-01

18
papers

1,295
citations

759233

12
h-index

888059

17
g-index

19
all docs

19
docs citations

19
times ranked

1446
citing authors

#	ARTICLE	IF	CITATIONS
1	Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. <i>Cell Metabolism</i> , 2015, 22, 1020-1032.	16.2	432
2	Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. <i>Kidney International</i> , 2016, 90, 985-996.	5.2	284
3	FGF23/FGFR4-mediated left ventricular hypertrophy is reversible. <i>Scientific Reports</i> , 2017, 7, 1993.	3.3	97
4	Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2028-2035.	0.7	86
5	Fibroblast growth factor 23 and Klotho contribute to airway inflammation. <i>European Respiratory Journal</i> , 2018, 52, 1800236.	6.7	78
6	Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1493-1503.	0.7	74
7	The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy. <i>Current Opinion in Nephrology and Hypertension</i> , 2016, 25, 314-324.	2.0	47
8	Klotho Inhibits Interleukin-8 Secretion from Cystic Fibrosis Airway Epithelia. <i>Scientific Reports</i> , 2017, 7, 14388.	3.3	36
9	Cardioprotective effect of calcineurin inhibition in an animal model of renal disease. <i>European Heart Journal</i> , 2011, 32, 1935-1945.	2.2	35
10	Pulmonary Hypertension Subtypes and Mortality in CKD. <i>American Journal of Kidney Diseases</i> , 2020, 75, 713-724.	1.9	32
11	STAT3-enhancing germline mutations contribute to tumor-extrinsic immune evasion. <i>Journal of Clinical Investigation</i> , 2018, 128, 1867-1872.	8.2	30
12	Cardioprotective Effects of Paricalcitol Alone and in Combination With FGF23 Receptor Inhibition in Chronic Renal Failure: Experimental and Clinical Studies. <i>American Journal of Hypertension</i> , 2019, 32, 34-44.	2.0	24
13	Soluble Klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease. <i>Kidney International</i> , 2022, 102, 261-279.	5.2	16
14	FGFR4 does not contribute to progression of chronic kidney disease. <i>Scientific Reports</i> , 2019, 9, 14023.	3.3	10
15	FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes. <i>Scientific Reports</i> , 2022, 12, 7326.	3.3	8
16	Induction of an Inflammatory Response in Primary Hepatocyte Cultures from Mice. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	5
17	Kidney to bone via bedside to bench and back?. <i>Journal of Clinical Investigation</i> , 2020, 130, 1106-1108.	8.2	1
18	Klotho-independent actions of FGF23 targets, signal transduction, and cellular effects. , 2021, , 65-77.		0